# US 2021/0060022 A1 · Treatment of cancers using pi3 kinase isoform modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060022 A1
- Document ID: US20210060022A1
- Status: Published application
- Kind: A1
- Application number: 16/848,485
- Filed: 2020-04-14
- Published: 2021-03-04
- Earliest claimed: 2012-11-01
- Assignees: Infinity Pharmaceuticals, Inc.
- Applicants: Infinity Pharmaceuticals, Inc.
- Inventors: Howard M. Stern; Jeffrey L. Kutok
- Web page: https://patentgrep.com/patent/US20210060022A1

## CPC

- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/52: Purines, e.g. adenine
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 473/00: Heterocyclic compounds containing purine ring systems
- C07D 473/34: attached in position 6, e.g. adenine
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/575: for cancer
- G01N 33/57505: of the blood, e.g. leukaemia
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 2333/521: Chemokines
- G01N 2333/525: Tumor necrosis factor [TNF]
- G01N 2333/53: Colony-stimulating factor [CSF]
- G01N 2333/5434: IL-12
- G01N 2333/9121: with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N 2333/96494: Matrix metalloproteases, e. g. 3.4.24.7
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods, kits, and pharmaceutical compositions that include a P13 kinase inhibitor for treating cancers or hematologic disorders.

## Claims

### Claim at position 1

-94. (canceled)

### Claim 95

A method of treating a hematologic malignancy in a human subject in need thereof, comprising orally administering to the subject twice daily about 15 mg to about 75 mg of a compound having the following structure or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof:

### Claim 96 (depends on 95)

The method of claim 95, wherein the hematologic malignancy has a high expression level of PI3K-δ, or PI3K-γ, or both PI3K-δ and PI3K-γ.

### Claim 97 (depends on 95)

The method of claim 95, wherein the compound or pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered in an amount sufficient to provide a plasma concentration of the compound at steady state at a level higher than the IC90 for PI3K-δ and at a level higher than the IC50 for PI3K-γ.

### Claim 98 (depends on 95)

The method of claim 95, wherein the compound or pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered in an amount sufficient to provide a plasma concentration of the compound at steady state of 300 ng/ml to 500 ng/ml.

### Claim 99 (depends on 95)

The method of claim 95, wherein the hematologic malignancy is a myeloid disorder, a lymphoid disorder, leukemia, lymphoma, myelodysplastic syndrome, a myeloproliferative disease, a mast cell disorder, myeloma, acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, acute T-cell leukemia, acute leukemia, acute B-cell leukemia, acute myeloid leukemia, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia, blast phase chronic myelogenous leukemia, small lymphocytic lymphoma (SLL), CLL/SLL, blast phase CLL, Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, indolent non-Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, aggressive B-cell non-Hodgkin lymphoma, B-cell lymphoma, Richter's syndrome, T-cell lymphoma, peripheral T-cell malignancy, peripheral T-cell lymphoma, cutaneous T-cell malignancy, cutaneous T-cell lymphoma, transformed mycosis fungoides, Sézary syndrome, anaplastic large-cell lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, lymphoplasmacytic lymphoma, Burkitt lymphoma, multiple myeloma, amyloidosis, essential thrombocytosis, myelofibrosis, polycythemia vera, chronic myelomonocytic leukemia, high-risk myelodysplastic syndrome, or low-risk myelodysplastic syndrome.

### Claim 100 (depends on 95)

The method of claim 95, wherein the hematologic malignancy is chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), CLL/SLL, indolent non-Hodgkin lymphoma, peripheral T-cell lymphoma, cutaneous T-cell lymphoma, or follicular lymphoma.

### Claim 101 (depends on 95)

The method of claim 95, wherein the hematologic malignancy is relapsed or refractory.

### Claim 102 (depends on 100)

The method of claim 100, wherein the hematologic malignancy is relapsed or refractory.

### Claim 103 (depends on 95)

The method of claim 95, wherein the hematologic malignancy is refractory to rituximab therapy, chemotherapy, and/or radioimmunotherapy.

### Claim 104 (depends on 95)

The method of claim 95, wherein the subject is identified as having a change in the serum concentration over time or relative to a reference or control level of a biomarker chosen from MMP-9, CXCL13, CCIA, CCLI 7, CCL22, or TNF-α, or a combination thereof

### Claim 105 (depends on 95)

The method of claim 95, wherein the compound or pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof is administered in combination with a second active agent selected from the group consisting of a BCL-2 inhibitor, a BTK inhibitor, an HDAC inhibitor, a MEK inhibitor, an EZH2 inhibitor, a PLK-1 inhibitor, an anti-CD37 antibody, an anti-CD20 antibody, and an anti-CD52 antibody.

### Claim 106 (depends on 105)

The method of claim 105, wherein the anti-CD20 antibody is selected from the group consisting of rituximab, tositumomab, ibritumomab, obinutuzumab and ofatumumab.

### Claim 107 (depends on 105)

The method of claim 105, wherein the HDAC inhibitor selected from the group consisting of belinostat, vorinostat, panobinostat, ACY-1215, and romidepsin.

### Claim 108 (depends on 105)

The method of claim 105, wherein the MEK inhibitor is selected from the group consisting of tametinib/GSK1120212, selumetinob, pimasertib/AS703026/MSC1935369, XL-518/GDC-0973, refametimb/BAY869766/RDEA119, PD-0325901, TAK733, MEK162/ARRY438162, R05126766, WX-554, R04987655/CH4987655, and AZD8330.

### Claim 109 (depends on 105)

The method of claim 105, wherein the EZH2 inhibitor is selected from the group consisting of EPZ-6438, GSK-126, GSK-343, Ell, and 3-deaz.aneplanocin A (DNNep).

### Claim 110 (depends on 105)

The method of claim 105, wherein the PLK-1 inhibitor is selected from the group consisting of volasertib (B16727), B12536, ZK-Thiazolidone, TAK-960, MLN0905, GSK461364, rigosertib (ON-01910), and HMN-214.

### Claim 111 (depends on 95)

The method of claim 95, comprising orally administering to the subject twice daily 15 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, or 50 mg of the compound.

### Claim 112 (depends on 95)

The method of claim 95, wherein the hematologic malignancy is relapsed or refractory chronic lymphocytic leukemia.

### Claim 113 (depends on 95)

The method of claim 95, wherein the hematologic malignancy is relapsed or refractory small lymphocytic lymphoma.

### Claim 114 (depends on 95)

The method of claim 95, wherein the hematologic malignancy is relapsed or refractory follicular lymphoma.
